Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2016 Jun;95(24):e3894.
doi: 10.1097/MD.0000000000003894.

Treated Glycosylated Hemoglobin Levels in Individuals With Diabetes Mellitus Vary Little by Health Status: A Retrospective Cohort Study

Free PMC article
Multicenter Study

Treated Glycosylated Hemoglobin Levels in Individuals With Diabetes Mellitus Vary Little by Health Status: A Retrospective Cohort Study

Finlay A McAlister et al. Medicine (Baltimore). .
Free PMC article

Erratum in


As choosing wisely has raised the issue of whether some individuals with type 2 diabetes may be overtreated, we examined the intensity of glycemic control across health status strata defined by comorbidities or frailty.This is a retrospective cohort study of commercially insured patients from 50 US states (Clinformatics Data Mart). We evaluated treated HbA1c levels in adults with new diabetes diagnosed between January 2004 and December 2009 who had HbA1C measured after at least 1 year of follow-up.Of 191,590 individuals with diabetes, 78.5% were otherwise healthy, 10.6% had complex health status (3 or more chronic conditions), and 10.9% were very complex (Johns Hopkins Adjusted Clinical Groups frailty marker or end-stage chronic disease). The proportion of patients who were tightly controlled (HbA1C <7%) was similar in otherwise healthy patients (66.1%) and in complex patients (65.8%, P = 0.37), and although it was lower (60.9%, P < 0.0001) in very complex patients, the magnitude of the difference was small. A substantial proportion of complex/very complex patients were taking sulfonylurea or insulin despite being at an increased risk for adverse effects from these agents and having tightly controlled HbA1C: 40.6% had HbA1C <7% and 24% had HbA1C <6.5%. Among patients with HbA1C <7%, use of insulin or sulfonylureas was associated with an increased risk for all-cause hospitalization [aHR 1.54, 95% confidence interval (95% CI) 1.45-1.64] and for emergency room visits (aHR 1.44, 95% CI 1.35-1.53) over the subsequent median 6 months follow-up.Diabetic control was similar regardless of comorbidity burden and frailty status. Despite being at a higher risk for adverse effects, nearly half of complex and very complex patients were still receiving insulin or sulfonylureas despite having treated HbA1C levels <7%, and these patients did exhibit higher risk of all-cause hospitalizations or emergency visits subsequently.

Conflict of interest statement

The authors have no conflicts of interest to disclose.


Figure 1
Figure 1
Derivation of study cohort.
Figure 2
Figure 2
Achieved glycemic control among adults with diabetes mellitus across 3 health status categories.

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles


    1. The Diabetes Control, Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86. - PubMed
    1. The Diabetes Control, Complications Trial/Epidemiology of Diabetes Interventions, Complications Study Research Group. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015;313:45–53. - PMC - PubMed
    1. Montori VM, Fernández-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med 2009;150:803–8. - PubMed
    1. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011;343:d6898. - PMC - PubMed
    1. Rodriguez-Gutierrez R, Lipska KJ, McCoy RG. Intensive glycemic control in type 2 diabetes mellitus – a balancing act of latent benefit and avoidable harm. A teachable moment. JAMA Intern Med 2016;176:300–1. - PMC - PubMed

Publication types